McKelvey-Martin V J, Ho E T, McKeown S R, Johnston S R, McCarthy P J, Rajab N F, Downes C S
Cancer and Ageing Research Group, School of Biomedical Sciences, University of Ulster, Coleraine, UK.
Mutagenesis. 1998 Jan;13(1):1-8. doi: 10.1093/mutage/13.1.1.
Management of invasive transitional cell human bladder carcinoma. The two main treatment options for invasive transitional cell bladder carcinoma are radiotherapy or primary cystectomy with urinary diversion or bladder substitution. Approximately 50% of patients fail to respond to radiotherapy and such patients so treated are disadvantaged by the absence of predictive information regarding their radiosensitivity, since the tumour gains additional time for metastatic spread before cystectomy is performed. The SF2 clonogenic assay, which measures the surviving fraction of tumour cells after 2 Gy X-ray irradiation, is regarded as a good measure of radiosensitivity. However, the assay is time consuming and provides results for only approximately 70% of human tumours. In this paper three bladder transitional cell carcinoma cell lines (HT1376, UMUC-3 and RT112) were exposed to X-irradiation (0-10 Gy). We have compared the responses obtained using a clonogenic assay and a more clinically feasible alkaline single cell gel electrophoresis (Comet) assay. A very good inverse correlation was obtained between cell survival (clonogenic assay) and mean tail moment (Comet assay) for the three cell lines, indicating that the Comet assay can be used to predict the radio-responsiveness of individual cell lines. The clinical usefulness of the assay for predicting response to radiotherapy in bladder cancer patients is currently being investigated. ABSTRACT II: Fluorescent in situ hybridization (FISH) Comets for the identification of damaged and repaired DNA sequences in individual cells. In mammalian cells the extent of DNA damage is partly and the rate of DNA repair very considerably dependent on DNA position and transcription. This has been established by biochemical techniques which are labour intensive and require large numbers of cells. The Comet assay for overall DNA damage and repair is relatively simple and allows individual cells to be examined. Here we present a protocol for combination of the Comet assay with fluorescent in situ hybridization (FISH) using a p53 gene probe which allows specific observation of p53 sequences within DNA comets. Chromosome-specific probes can also be used. Optimization of the FISH/Comet protocol to include automation of the analysis is currently underway to facilitate future application of the technique to study selective DNA damage and repair in defined sequences in single mammalian cells.
摘要I:浸润性人膀胱移行细胞癌的管理。浸润性膀胱移行细胞癌的两种主要治疗选择是放射治疗或行原发性膀胱切除术并进行尿流改道或膀胱替代术。约50%的患者对放射治疗无反应,接受此类治疗的患者因缺乏关于其放射敏感性的预测信息而处于不利地位,因为在进行膀胱切除术之前,肿瘤有更多时间发生转移扩散。SF2克隆形成试验可测量2 Gy X线照射后肿瘤细胞的存活分数,被认为是放射敏感性的良好指标。然而,该试验耗时且仅能为约70%的人类肿瘤提供结果。在本文中,三种膀胱移行细胞癌细胞系(HT1376、UMUC - 3和RT112)接受了X线照射(0 - 10 Gy)。我们比较了使用克隆形成试验和更具临床可行性的碱性单细胞凝胶电泳(彗星试验)获得的结果。对于这三种细胞系,细胞存活(克隆形成试验)与平均尾矩(彗星试验)之间获得了非常好的负相关,表明彗星试验可用于预测单个细胞系的放射反应性。目前正在研究该试验在预测膀胱癌患者放射治疗反应方面的临床实用性。摘要II:用于识别单个细胞中受损和修复的DNA序列的荧光原位杂交(FISH)彗星试验。在哺乳动物细胞中,DNA损伤的程度部分取决于且DNA修复的速率很大程度上取决于DNA位置和转录。这已通过劳动强度大且需要大量细胞的生化技术得以证实。用于检测总体DNA损伤和修复的彗星试验相对简单,可对单个细胞进行检测。在此,我们展示了一种将彗星试验与使用p53基因探针的荧光原位杂交(FISH)相结合的方案,该方案可对DNA彗星内的p53序列进行特异性观察。也可使用染色体特异性探针。目前正在对FISH/彗星试验方案进行优化,包括实现分析自动化,以便于该技术未来应用于研究单个哺乳动物细胞中特定序列的选择性DNA损伤和修复。